

David Olmos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5747476/publications.pdf>

Version: 2024-02-01

25
papers

4,607
citations

471509

17
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

5414
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
2	Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1408-1418.	27.0	947
3	Germline <i>BRCA</i> Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1748-1757.	1.6	641
4	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
5	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. <i>European Urology</i> , 2015, 68, 186-193.	1.9	279
6	PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 490-503.	1.6	255
7	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , 2017, 71, 417-425.	1.9	169
8	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	10.7	97
9	BRCA2 and Other DDR Genes in Prostate Cancer. <i>Cancers</i> , 2019, 11, 352.	3.7	72
10	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	6.4	63
11	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	1.3	58
12	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2019, 11, 1355.	3.7	54
13	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , 2021, 147, 74-83.	2.8	42
14	Circulating and disseminated tumor cells in ovarian cancer: A systematic review. <i>Gynecologic Oncology</i> , 2014, 133, 632-639.	1.4	37
15	Targeting DNA Repair. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 353-356.	2.0	27
16	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e223-e231.	1.9	27
17	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	3.7	22
18	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 2855.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	3.7	15
20	Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients. <i>European Urology Oncology</i> , 2021, 4, 315-318.	5.4	6
21	Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5020-5020.	1.6	5
22	Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5056-5056.	1.6	4
23	Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 164-164.	1.6	2
24	Implications of DNA damage repair alterations for the management of prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 302-310.	1.8	1
25	Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5060-5060.	1.6	1